Apyx Medical's 2024 Proxy Reveals Stable Equity Compensation Trends

TL;DR

Apyx Medical's 2024 proxy shows a puzzling lack of vested equity for top execs, raising questions about future incentives and performance alignment.

AI Summary

Apyx Medical Corp's DEF 14A filing for the fiscal year ended December 31, 2024, provides insights into executive compensation and governance, but lacks specific revenue and net income figures for the period. The filing details equity awards granted to both named executive officers (PEO) and non-named executive officers (NEO), indicating a focus on performance-based incentives. For instance, the fair value of equity awards granted and vested for PEOs was $0 in 2024, consistent with 2023 and 2022, suggesting a potential shift in compensation structure or a lack of new grants vesting in the period. The change in fair value of outstanding and unvested equity awards for PEOs was $0 in 2024, also mirroring 2023 and 2022. The company, operating in the surgical and medical instruments sector, continues to navigate a competitive landscape, with its strategic outlook likely tied to product innovation and market penetration. Key business changes or specific risks related to operations or financial performance are not explicitly detailed in this particular DEF 14A, which primarily focuses on proxy-related disclosures.

Why It Matters

This DEF 14A filing is crucial for investors as it outlines Apyx Medical Corp's executive compensation practices and corporate governance for the 2024 fiscal year, directly impacting shareholder value and alignment. The consistent $0 fair value for vested equity awards for PEOs across 2022-2024 could signal a deliberate compensation strategy or a pause in certain equity grants, which investors should scrutinize. For employees, the compensation structure, particularly for NEOs, reflects the company's approach to talent retention and motivation within the competitive medical device industry. Customers and the broader market are indirectly affected by the company's leadership stability and incentive structures, which can influence long-term innovation and operational efficiency.

Risk Assessment

Risk Level: medium — The risk level is medium because the DEF 14A filing, while providing compensation data, does not include specific financial performance metrics like revenue or net income for 2024, making it difficult to assess the company's operational health. The consistent $0 fair value for vested equity awards for PEOs from 2022 to 2024 could indicate a lack of performance-based vesting or a shift away from equity incentives, which might impact executive motivation and long-term strategic execution.

Analyst Insight

Investors should demand greater transparency regarding Apyx Medical's executive compensation rationale, especially the consistent $0 vested equity for PEOs, and seek detailed financial performance data for 2024. Scrutinize future filings for any changes in compensation philosophy or new equity grant programs that better align executive incentives with shareholder returns.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

0%

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

0%

cash Position

$0

revenue Growth

+0%

Executive Compensation

Key Numbers

• $0 — Fair Value of Vested Equity Awards (PEO) (Consistent for PEOs in 2022, 2023, and 2024, indicating no vested equity awards for top executives in these periods.)
• $0 — Change in Fair Value of Outstanding and Unvested Equity Awards (PEO) (Consistent for PEOs in 2022, 2023, and 2024, suggesting no change in the value of unvested awards for top executives.)
• 2024-12-31 — Fiscal Year End (The period covered by the DEF 14A filing.)
• 001-31885 — SEC File Number (Unique identifier for Apyx Medical Corp's SEC filings.)

Key Players & Entities

• Apyx Medical Corp (company) — Filer of DEF 14A
• SEC (regulator) — Recipient of DEF 14A filing
• 0000719135 (company) — Central Index Key (CIK) for Apyx Medical Corp
• Clearwater, FL (company) — Business address location for Apyx Medical Corp
• Bovie Medical Corp (company) — Former name of Apyx Medical Corp
• AN CON GENETICS INC (company) — Former name of Apyx Medical Corp
• $0 (dollar_amount) — Fair value of equity awards granted and vested for PEOs in 2024
• 2024-12-31 (date) — Conformed period of report end date
• 2025-06-25 (date) — Filed as of date for the DEF 14A
• DEF 14A (regulator) — SEC filing form type

FAQ

Industry Context

Apyx Medical Corp operates in the surgical and medical instruments sector, a competitive landscape driven by technological innovation and market penetration. Companies in this industry focus on developing and commercializing advanced medical devices to improve surgical procedures and patient outcomes.

Regulatory Implications

As a medical device company, Apyx Medical Corp is subject to stringent regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance is critical. Changes in healthcare policy or reimbursement rates can also impact the company's financial performance.

What Investors Should Do

1. Monitor future filings for detailed financial performance.
2. Analyze the rationale behind the $0 equity awards for PEOs.

Key Dates

• 2024-12-31: Fiscal Year End — Marks the end of the reporting period for the DEF 14A filing.
• 2025-06-25: Filing Date — The date the DEF 14A filing was submitted to the SEC.

Glossary

DEF 14A

A proxy statement filing required by the SEC for companies with securities registered under Section 12 of the Securities Exchange Act of 1934. It provides detailed information about executive compensation, corporate governance, and matters to be voted on by shareholders. (This is the primary document analyzed, providing insights into executive compensation and governance practices.)

PEO

Principal Executive Officer, typically the Chief Executive Officer (CEO) of a company. (Used to identify compensation and equity award details specifically for the top executive.)

NEO

Named Executive Officer, a group of top executives including the CEO, CFO, and other highest-paid officers. (Used in compensation disclosures, though this filing focuses on PEOs for specific equity award data.)

Equity Awards

Awards granted to employees, typically executives, in the form of company stock, stock options, or other equity-based instruments. (Key component of executive compensation, often tied to performance and long-term incentives.)

Fair Value

The estimated price at which an asset would change hands between a willing buyer and a willing seller, neither being under any compulsion to buy or to sell, and both having reasonable knowledge of relevant facts. (Used to quantify the value of equity awards granted and their changes over time.)

Year-Over-Year Comparison

This DEF 14A filing for the fiscal year ended December 31, 2024, indicates a consistent approach to executive compensation compared to prior years, with $0 reported for the fair value of vested equity awards and the change in fair value of outstanding and unvested equity awards for PEOs. Specific financial performance metrics like revenue and net income for 2024 are not detailed in this proxy statement, making a direct comparison of financial highlights to the previous year impossible based solely on this document. The filing does not explicitly detail new risks or significant business changes.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 25, 2025 regarding Apyx Medical Corp (APYX).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR